CRVS ORBIMED ADVISORS LLC sells $4.9M worth of shares
Jul 02, 2025, 4:36 AM
0.00%
What does CRVS do
Corvus Pharmaceuticals, a clinical-stage biopharmaceutical company based in Burlingame, California, develops immune modulators for cancers and autoimmune diseases, with key products including soquelitinib and ciforadenant. Founded in 2016, it employs 28 people and focuses on innovative immunotherapy approaches.
ORBIMED ADVISORS LLC sold 1,176,332 shares of CRVS on 27 June at $4.16 per share, worth a total of $4.9M. They now own 7,165,006 CRVS shares, or a 14% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.